



Pulmonary thrombo-endarterectomy for chronic thromboembolic pulmonary artery hypertension

Sofia Martin-Suarez¹, Gregorio Gliozzi¹, Antonio Loforte¹, Fabio Niro², Mariafrancesca Fiorentino¹, Giulio Giovanni Cavalli¹, Massimiliano Palazzini³, Francesco Saia³, Niccolò Barbera⁴, Marco La Monaca⁵, Nazzareno Galiè³, Davide Pacini¹

¹Cardiac Surgery Unit, Cardio Thoracic and Vascular Department, Bologna University, Bologna, Italy; ²Interventional Radiology Unit, Cardio Thoracic and Vascular Department, Bologna University, Bologna, Italy; ³Cardiology Unit, Cardio Thoracic and Vascular Department, Bologna University, Bologna, Italy; ⁴CardioThoracic Anaesthesia Unit, Cardio Thoracic and Vascular Department, Bologna University, Bologna, Italy; ⁵Clinical Perfusionist, Cardio Thoracic and Vascular Department, Bologna University, Bologna, Italy

Contributions: (I) Conception and design: S Martin-Suarez, D Pacini; (II) Administrative support: None; (III) Provision of study materials or patients: G Gliozzi, S Martin-Suarez; (IV) Collection and assembly of data: S Martin-Suarez, G Gliozzi, GG Cavalli; (V) Data analysis and interpretation: S Martin-Suarez, G Gliozzi; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Sofia Martin-Suarez, MD, PhD. Cardiac Surgery Unit, Cardio Thoracic and Vascular Department, Bologna University, S.Orsola Hospital, Pad 23 POLO CTV, Via Massarenti 9, 40138, Bologna, Italy. Email: docsofi74@hotmail.com; sofia.martinsuarez@aosp.bo.it.

Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is the only type of pulmonary hypertension (PH) with a surgical treatment aimed to remove fibrotic thrombus allowing a significant lowering of pulmonary vascular resistances (PVR) or even normalisation of PH. Pulmonary thrombo-endarterectomy (PTE) is performed through full median sternotomy, cardiopulmonary bypass (CPB) with periods of deep hypothermic circulatory arrest (DHCA). Diagnostic process, patient selection, surgical and postoperative management require specific expertise and a multidisciplinary team as we have in our department. In the present paper we will expose our single-center 17-year retrospective experience on PTE.

Methods: We present a cohort of 177 consecutive PTE patients underwent surgery in two different “Eras”: groups 1 and 2, with 96 and 81 patients respectively. During the first period (2003 to 2012) DHCA was applied strictly if venous pulmonary back-bleeding precluded a complete endarterectomy, while during the second era [2012–2020] DHCA was routinely adopted during CPB. Retrospective analysis of preoperative data, as well as surgical characteristics and postoperative outcome have been compared between groups.

Results: Some differences on preoperative clinical and hemodynamic data have been found, as the incidence of concomitant chronic pulmonary disease and more decompensated profile in the first group. On the other hand, in group 2, a larger number of patients were preoperatively treated with specific pulmonary vasodilators. Cross clamp time as well as time of CPB were significantly shorter in group 2 in spite of a mean DHCA time of 33 minutes. In-hospital mortality was 15.6% and 3.7%, in groups 1 and 2 respectively. Pulmonary hemodynamic as well as long term outcome equally and significantly improved in both groups.

Conclusions: Our experience demonstrates that, as in other fields of cardio-thoracic surgery, learning curve strongly impact on results: multidisciplinary preoperative evaluation and selection of patients, surgical planning and well-defined intra- and post-operative protocols contribute to improve hemodynamics and clinical outcomes. This assertion acquires more sense since this pathology is considered a rare one, requiring deep knowledge on its pathophysiology, diagnostic procedures, therapeutic alternatives, as well as specific skills on surgical and anaesthetic management. Our CTEPH center offers all the needed pathway, from diagnostic to therapeutic alternatives, with excellent results.

Keywords: Pulmonary hypertension (PH); thromboembolic; endarterectomy; deep hypothermic circulatory arrest

Received: 06 August 2020; Accepted: 16 December 2020; Published: 25 May 2021.

doi: 10.21037/ccts-20-137

View this article at: <http://dx.doi.org/10.21037/ccts-20-137>

Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH) is defined as an increase of mean pulmonary artery pressure (PAPm) over 25 mmHg associated with defects of pulmonary arteries patency, after at least 3 months of full and efficient anticoagulation. CTEPH is a long term consequence of an unsolved or not recognised acute pulmonary embolism and, if untreated, has a poor prognosis. Clots turn fibrotic and strongly adhere to the arterial walls, narrowing or occluding the lumen at different levels. CTEPH is a rare disease, with a tricky differential diagnosis. A clinical history of previous acute pulmonary embolism is not always present and it is estimated that less than 40% of patients have an episode of acute pulmonary embolism (1). Clinical presentation includes many unspecific symptoms, such as progressive exertional dyspnea, palpitations, hemoptysis, syncope and venous congestion. Patients show various hemodynamic profiles and different degrees of pulmonary hypertension (PH), not always proportional to the extent of pulmonary arteries occlusion: in fact, in the small arteries not involved by chronic pulmonary embolism, the overflow is at first associated to vasoconstriction and then to a progressive structural remodeling with wall hypertrophy, increasing pulmonary vascular resistances (PVR) progressively (2,3). Additionally, there are asymptomatic patients with chronic thromboembolic pulmonary lesions without PH, representing another controversial pathological entity, the so-called chronic thromboembolic disease (CTED). CTEPH is the only kind of PH with a potentially curative surgical treatment different from lung transplantation: the pulmonary thrombo-endarterectomy (PTE). However, operability assessment is a complex process, made by a multidisciplinary and dedicated team, including pulmonologists, cardiologists, radiologists and surgeons. Possibly, the most important factor in determining surgical feasibility is the correlation of severity of PH versus the extent of the obstruction. Individual patient factors, including comorbidity and the level of expectations for long-term benefits, are crucial in the decision-making process. PTE operation requires a team of dedicated and trained surgeons as well as critical care expert physicians in the postoperative period. As a general rule, PTE follows four basic principles: (I) the endarterectomy must be bilateral, therefore anterior approach through median sternotomy is mandatory; (II) a clear surgical field is essential: this is obtained through deep hypothermic (at 20 °C)

cardiopulmonary bypass (CPB) associated with periods of circulatory arrest; (III) identification of the correct dissection plane is crucial to reduce vascular resistances as much as possible; (IV) a complete endarterectomy reaching sub-segmental arteries is essential (4).

PTE surgeons should carefully evaluate preoperative anatomy in order to forecast if a complete endarterectomy is practicable: only few patients show distal lesions beyond segmental arteries. Although distal anatomy it is not an absolute contraindication to surgery (it only makes harder the surgical dissection, with longer surgical times), CTEPH teams could now offer an alternative therapeutic option: in inoperable patients or in patients with recurrent/persistent PH after PTE, the balloon pulmonary angioplasty (BPA) is a good second choice.

The CTEPH complex diagnosis, its epidemiology, the heterogeneous clinical expressions and the different therapeutic options, are the main reasons that justify that only dedicated and expert CTEPH centers must take care of these patients, being few in every country. Ours is one of the two dedicate centers in Italy, and the only one able to offer the entire therapeutic diagnostic path to the patient affected by CTEPH.

In the present paper we will expose our 17 years of experience on PTE.

We present the following article in accordance with the STROBE reporting checklist (available at <http://dx.doi.org/10.21037/ccts-20-137>).

Methods

From 2003 to 2020, we performed 177 PTE. Our center is a national referral center for PH. CTEPH patient represents 30% of all referred PH patients with a prevalence of nearly 40 cases per million of inhabitants. Some of this patients are referred to our center with the CTEPH diagnosis already made. Many patients reach our center with unspecific PH diagnosis, mostly because very distal and imperceptible disease, and CTEPH diagnosis is made by us. As expert center, we complete diagnosis and assessment in order to offer the patient the best therapeutic solution. Every single case of CTEPH is formally discussed in the multidisciplinary meeting, where pulmonary angioTC scan, angiography, catheterisation, echocardiography are deeply analysed. PTE, BPA or medication are the three therapeutic options, being PTE the first choice. BPA or medical therapy are intended for patients considered not good




Figure 1 Intraoperative pictures of a PTE operation. (A) Recognition of cleavage plane; (B) surgical specimen. PTE, pulmonary thromboendarterectomy.

candidates to surgery, depending on anatomy, hemodynamic and comorbidities. Operation is made through median sternotomy. After pericardiotomy, CPB is started with a cannula in the ascending aorta and two venous cannulae in the cava, the superior one positioned directly from the right atrial appendage to avoid right pulmonary exposure obstacle. Also the main pulmonary artery and the left ventricle are drained. Once the CPB begins, the systemic cooling proceeds progressively, maintaining a minimum thermal gradient. While cooling, myocardial protection and aortic cross clamping (ACC) are achieved. In our center we use crystalloid Custodiol Solution (5). At the beginning of our experience, we entered into a protocol aimed to avoid deep hypothermic circulatory arrest (DHCA). At 25 degrees of core temperature, pump flow could be lowered until even less than one liter per minute, while maintaining good perfusion parameters in particularly the mixed venous oxygen saturation (>65%). At a very low pump flows, the back flow can be as scarce as in arrest, allowing a complete endarterectomy. The main disadvantage of this method and in an unpredictable manner (perhaps the extent of collateral bronchial circle could serve as an indicator) in spite of a minimum pump flow, the retrograde flow is making it impossible to impose endarterectomy (6,7). This constrains to go back to pump full flow to reach 20 degrees of temperature and proceed with the DHCA, prolonging in these cases the extracorporeal circulation (CPB) and aortic cross-clamping times. That's why since 2012 until now and to stay in line with the greatest experts in PTE, we have decided to directly adopt deep hypothermia at 20 degrees with periods of 20 minutes of circulatory arrest interspersed with 10 minutes of isothermal reperfusion if procedure prolongs. Other authors have demonstrated any advantage by adopting different methods than DHCA (8). Right

and longitudinal arteriotomy is performed, and cleavage plane identified. Progressively the fibrotic thrombus is detached from the wall and pulled back until the very distal branches (*Figure 1*). After the right endarterectomy is concluded and the artery reconstructed, the PTE in the left side is performed in the same fashion. Once bilateral PTE is completed, the patient is progressively rewarmed until normothermia. If associated procedures are indicated, like coronary bypass, those are performed during the rewarming period. Then CPB is stopped and hemostasis and wound closure done in the usual way. During and after the operation, management of water balance, electrolyte control, cardiac output as well as peripheral systemic resistance, and anticoagulation are some of the fundamental aspects that require very delicate adjustments, being a topic worthy to be deeply detailed in another paper.

Patients were followed up at 3, 6, and 12 months and then yearly with echocardiogram, and 6-minute walk distance (6MWD). Right heart catheterization was performed when patients experienced deterioration in New York Heart Association (NYHA) Functional Class, remained in Class III after PEA, or presented with persistent deterioration in the 6MWD in the presence of residual PH on echocardiogram.

Our cardiovascular surgery center of Sant'Orsola Hospital in Bologna (Italy) was born in 1974, being an Italian and European reference in aortic surgery and cardiac transplantation. Thanks to our huge experience in those two fields and also to the close collaboration with Prof. N. Galié, world's leading expert in PH, in 2003 we established the PTE program, after learning from experts like Prof. Jamieson from San Diego. We have performed 177 PTE in 174 patients in 17 years (three patients underwent PTE reoperation because of CTEPH recurrence, mainly due to

a high thrombophilic risk profile). We have retrospectively divided the population in two groups depending on the use or not of DHCA. The group 1, includes 96 patients operated until 2012, while group 2, 81 consecutive patients from 2012 until 2020. DCHA was adopted in the second era group.

Statistical analysis

Continuous variables were expressed as mean and standard deviation while categorical variables were expressed as numbers and percentage. Descriptive statistical analysis was performed through chi-square and Student's *t*-test, when appropriate. Operative mortality was defined as death within 30 days of surgery and within the same hospital admission. Survival after surgery was estimated using the life-table and Kaplan-Mayer analysis: differences were tested by the log-rank test. Survival was calculated from the date of surgery. Predictors of mortality were identified by using univariate logistic regression analysis. IBM SPSS Statistics 24 was used for all analyses. Values of $P < 0.05$ were considered significant.

Ethical statement

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization. Our institution does not require a review board approval for retrospective studies and informed consent form was waived.

Results

Of 485 CTEPH patients in our center, 37 do not suffer of PH being categorized as CTED and none of them undergone PTE or BPA. All cases of CTEPH have been discussed in the dedicated multidisciplinary meeting. Around 56.9% cases, did not have indication to any kind of re-perfusion therapy, intended as PTE or BPA. Of the remaining CTEPH population, nearly 80% PTE was indicated and performed. The 63% of patient reach the operation under specific pulmonary vasodilator therapy. Preoperative population characteristics, echocardiography and hemodynamics are described in *Table 1*. The most relevant preoperative differences between groups were that in the group 1, patients were smaller with only 16.7% of

patients with a body mass index more than 30 kg/m^2 respect the 28.8% in the group 2 ($P < 0.05$). In group 1, 58.3% of patients suffered from some degree of associated chronic obstructive pulmonary disease (COPD) while in group 2 only 29.6% ($P < 0.000$). Previous acute pulmonary embolism was documented in 44.8% and 75% of patients in group 1 and 2 respectively ($P < 0.000$). Almost 80% of patients in group 2, reach the operation with some pulmonary vasodilator therapy respect the 56% of group 1 ($P = 0.001$). From a hemodynamic point of view, both groups were comparable, even in the group 1 patients appeared more decompensated, with a higher central venous pressure and a lower right ventricular shortening fraction (RVSF).

As described in the methods, also in group 1, even if trying to avoid DHCA, the surgeon was in implacable necessity to adopt it because inability to perform correctly the PTE. That occurred in more than 50% of patients (54.2%). Also in group 2, while reaching the core temperature of 20 degrees and preparing the cleavage plane, the PTE was feasible to perform without the need of systemic arrest, but that happened only in 4 cases (4.9%); 60% of patients required 2 period of DHCA, one for each side, 22.2% required 3 and only 8% more than 3 in group 2. Mean time of DHCA was 21 ± 19 minutes for all cohort, while was 12 ± 11 and 33 ± 16 minutes in group 1 and group 2 respectively. Those numbers mirror that probably in group 1, when DHCA was necessarily required, yes it prolonged the cross clamp time, but the arrest was necessary just to detach the very distal part of the fibrotic thrombus. In 7.2% of cases in group 1, other cardiac procedures were associated respect 3.7 (excluding the closure of the patent foramen ovalis) ($P = 0.003$). In group 1, cross clamp times was 40 minutes longer than group 2. Specific surgical data are represented in *Table 2*.

Postoperative hemodynamics and outcomes are reported in *Table 3*. Pulmonary hemodynamics improved equally in both groups reaching a PAPm of 25.2 ± 6.7 mmHg and PVR of 4.3 ± 3.0 Wood units (WU). In 80% of the cases an immediate reduction of 36% of the preoperative PH values was observed, which exceeded 50% in the 24 successive hours. In 32% of the cases, a complete normalization of the pulmonary pressure values occurred before invasive monitoring was interrupted, generally in 4th to 5th postoperative day (POD).

Length of stay in intensive care unit and overall hospitalization were 7.9 and 19 days respectively. Main complication after surgery were, 13.6% re-thoracotomy for excessive blood loss from drains, pneumonia in 16.4% of

Table 1 Preoperative population data

Preoperative characteristics	Overall (n=177), n (%)	2003–2011 (n=96), n (%)	2012–2020 (n=81), n (%)	P value
Age, years	57.9±15.7	56.9±16.2	59.1±15.2	0.353
Male	63 (35.6)	40 (41.7)	23 (28.4)	0.066
BMI, kg/m ²	26.1±5.0	25.4±4.5	27.0±5.5	0.032*
BMI >30 kg/m ²	39 (22.2)	16 (16.7)	23 (28.8)	0.055
BSA, m ²	1.8±0.2	1.8±0.2	1.8±0.2	0.213
Hypertension	83 (46.9)	45 (46.9)	38 (46.9)	0.996
Diabetes mellitus	7 (4.0)	4 (4.2)	3 (3.7)	0.594
Dyslipidemia	58 (32.8)	34 (42.2)	24 (25.0)	0.017*
Coronary artery disease	19 (10.7)	12 (12.5)	7 (8.6)	0.409
Previous acute PE	103 (58.5)	43 (44.8)	60 (75.0)	0.000*
Previous DVT	82 (47.4)	41 (43.2)	41 (52.6)	0.218
Previous malignancy	52	27	25	0.612
Onset between symptoms and intervention, months	40.5±47.8	39.7±48.5	41.6±47.1	0.800
NYHA III-IV	117 (66.1)	70 (72.9)	47	0.349
Anticoagulants	175 (98.9)	96 (100.0)	80 (98.8)	0.545
Vasodilators	118 (66.7)	54 (56.2)	64 (79.0)	0.001*
Chronic lung disease	80 (45.2)	56 (58.3)	24 (29.6)	0.000*
DLCO	62.2±16.9	60.6±17.4	65.8±15.5	0.194
FEV1	88.3±18.2	88.6±18.4	88.1±17.9	0.889
O ₂ therapy	50 (28.2)	28 (29.2)	24 (29.6)	0.940
Thrombophilia	52 (29.4)	30 (31.3)	22 (27.2)	0.703
REDO	11 (6.2)	7 (7.3)	4 (4.9)	0.518
Echocardiogram				
LVEF, %	66.9±7.3	67.9±8.0	65.7±6.1	0.043*
RVSF, %	26.7±9.6	25.1±9.2	29.2±9.7	0.015*
P _{RV} , mmHg	81.2±21.4	81.3±21.8	81.0±21.1	0.940
Hemodynamics				
PAPs, mmHg	84.7±19.1	85.3±19.5	84.0±18.8	0.647
PAPd, mmHg	26.4±11.1	27.2±11.6	25.4±10.4	0.270
PAPm, mmHg	48.4±13.1	49.5±13.2	47.1±12.9	0.235
RAP, mmHg	8.1±5.2	9.2±6.1	6.7±3.6	0.001*
PWCP, mmHg	9.6±4.6	10.0±5.6	9.2±3.0	0.252
CO, L/min	4.7±1.4	4.6±1.5	4.8±1.3	0.246
CI, L/min/m ²	2.6±0.7	2.6±0.7	2.7±0.7	0.392

Table 1 (continued)

Table 1 (continued)

Preoperative characteristics	Overall (n=177), n (%)	2003–2011 (n=96), n (%)	2012–2020 (n=81), n (%)	P value
TPG, mmHg	38.5±10.6	39.4±11.5	37.3±9.1	0.208
PVR, WU	9.1±3.7	9.5±3.9	8.6±3.4	0.131
PVR, dynes	728.0±295.2	759.0±311.1	691.3±272.5	0.131
Hemodynamic classification (dynes)				
1–400	23 (13.0)	13 (13.5)	10 (12.3)	0.705
401–800	87 (49.1)	44 (45.9)	43 (53.0)	
801–1,200	53 (30.0)	30 (31.3)	23 (28.5)	
>1,200	12 (6.8)	8 (8.3)	4 (5.0)	
Missing	2 (1.1)	1 (1.0)	1 (1.2)	
AngioCT scan involvement				
Central	59 (33.3)	35 (36.5)	24 (29.6)	0.402
Lobar	109 (61.6)	59 (61.5)	50 (61.7)	0.872
Segmental	154 (87.0)	83 (86.5)	71 (87.7)	0.606
Subsegmental	97 (54.8)	58 (60.4)	39 (48.1)	0.145

* indicates significance ($P < 0.05$). BMI, body mass index; BSA, body surface area; PE, pulmonary embolism; DVT, deep venous thrombosis; NYHA, New York Heart Association; DLCO, diffusion lung carbonmonoxyde; FEV₁, forced expiratory volume; LVEF, left ventricle ejection fraction; RVSF, right ventricle systolic function; P_{RV}, right ventricle pressure; PAP, pulmonary artery pressure; RAP, right atrial pressure; PWCP, pulmonary wedge capillary pressure; CO, cardiac output; CI, cardiac index; TPG, trans pulmonary gradient; PVR, pulmonary vascular resistances; WU, Wood units.

cases, and dialysis in 3.4% of cases. There were two cases of permanent neurological dysfunction (PND) in group 2: one, a 34 years old female patient, who was operated on cardiac arrest because of massive CTEPH, who suffered from a temporal small ischemic damage causing visus deficit and second one a 78 years old female who had a major brain hemorrhage suddenly after the operation. Overall incidence of PND of 177 cases was 1.1%. Transitory neurological deficit (TND) happened in 8 patients, characterized in 5 of them by choreoathetosis and in the other three cases by transitory confusion. Extra-corporeal membrane oxygenator (ECMO) was required in 22 patients (12.4%) lasting an average of 10.3±7.9 days. Even without statistically significance, ECMO was implanted in 15.6% of patient in group 1 while only in 8.6% in group 2. ECMO was mainly implanted by a peripheral approach and dominant indication was residual over systemic PH and/or right ventricular failure. Mortality in ECMO was 50%. Successful Weaning from ECMO was feasible in the 46.5% and 57.1% of patients in group 1 and 2 respectively. Of the eleven weaned patients, 3 subsequently died because septic

shock, multiorgan failure and cardiorespiratory failure; 72% of weaned patient survived. Specifically, in group 1, ECMO was needed exactly in 16.6% of cases where DHCA was avoided (8/48) respect 10.9% in those operated on DHCA (14/128). More data about ECMO after PEA, and our management policy can be found in a recent published article, based on 154 PTE cases (9).

Operative mortality was 10.2 being 15.6% and 3.7% from the groups 1 and 2. Univariate inference demonstrated as risk factors for operative mortality, being part of group 1, high PVR values, worst preoperative functional class, associated COPD, higher CVP and longer operation time. Risk factors for ECMO at the univariate analysis are almost the same, except the era, while the cross clamp time represents a higher risk of ECMO. Univariate analysis is reported in Table 4.

Mean follow up time was 66.7±42.2 months. The long-term survival represented in the Kaplan Mayer curves (Figure 2) demonstrated a significant difference (Log rank =0.008) between groups, mostly due to the higher mortality in group 1. Nearly 93% of PTE patient are free of specific

Table 2 Intraoperative data

Intraoperative characteristics	Overall (n=177), n (%)	2003–2011 (n=96), n (%)	2012–2020 (n=81), n (%)	P value
X-clamp time, min	161±48	180±44	139±43	0.000*
CPB time, min	284±67	291±77	275±59	0.131
DHCA	128 (72.3)	52 (54.2)	76 (93.8)	0.000*
Total DHCA time, min	21±19	12±17	33±16	0.000*
Periods of DHCA				0.000*
0	48 (27.1)	44 (45.8)	4 (4.9)	
1	37 (20.9)	32 (33.3)	5 (6.2)	
2	58 (32.8)	11 (11.4)	47 (58)	
3	25 (14.1)	7 (7.3)	18 (22.2)	
>3	9 (5.1)	2 (2.0)	7 (8.6)	
Associated procedures	48 (27.1)	35 (36.4)	13 (16)	0.003*
Septal defects	38 (21.5)	28 (29.2)	10 (12.3)	
CABG	6 (3.4)	3 (3.1)	3 (3.7)	
Valvular	3 (1.7)	3 (3.1)	0 (–)	
Other	1 (0.5)	1 (1.0)	0 (–)	

* indicates significance ($P<0.05$). X-clamp time, aortic cross clamp time; CPB, cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; CABG, coronary artery bypass.

pulmonary vasodilator drugs and 66% had normalization of PH values. A total of 5 patients, required balloon angioplasty in the follow-up. None of our patients died in the follow up because of cardiac failure secondary to CTEPH. Four patients required PTE reintervention after PEA, one 46 years old lady, who underwent second PTE 4 years after first PTE performed elsewhere with very high PH, who need postoperative ECMO, weaned and treated with BPA because of residual PH; three other patients (1.7% of recurrence) were operated the first time in our center, and after 4, 6 and 5 years each, they require a second PTE. All of them had lupus anticoagulant syndrome.

Discussion

We have retrospectively presented 17 years of experience in pulmonary thromboendarterectomy performed in 174 patients for a total of 177 procedures. At the beginning of our experience in 2002/2003, and despite having attended the most expert center in the world and founder of PTE, that is the center of Prof. Jamieson in San Diego (10), we adopted an alternative technique to

that traditionally accepted by all experts. Technique based on a different management of the CPB avoiding deep hypothermia and arrest of the circulation (DHCA), in line with our policy in aortic arch surgery based on the use of moderate hypothermia at 25 °C, given the widely reported neurological and coagulation complications related to use of DHCA (11).

Our technique involved the conventional PTE operation, but reducing the flow of extracorporeal circulation to the minimum one, necessary to maintain good tissue perfusion values and with minimal retrograde flow, allowing a complete pulmonary endarterectomy to be performed perfectly.

As previously described, the results in terms of improvement and resolution of the PH values were satisfactory, but frequently, it was indispensable to appeal to DHCA while on myocardial cardioplegic arrest, significantly increasing the times of CPB and aortic clamping. For this reason, since 2012, thanks also to the advice and guidelines of the main expert task forces (12), we have routinely adopted the DHCA.

We have then compared the two cohorts (group 1,

Table 3 Postoperative data

Early outcomes	Overall (n=177), n (%)	2003–2011 (n=96), n (%)	2012–2020 (n=81), n (%)	P value
Hemodynamics				
PAPs, mmHg	39.4±11.8	39.9±11.4	38.8±12.3	0.543
PAPd, mmHg	17.5±6.2	18.0±6.4	16.8±5.9	0.200
PAPm, mmHg	25.2±6.7	25.3±6.6	24.8±6.8	0.639
RAP, mmHg	7.0±2.5	7.0±2.6	7.0±2.3	0.967
TPG, mmHg	16.2±6.6	16.4±6.3	15.9±7.2	0.700
PVR, UW	4.2±2.7	4.3±3.0	3.9±2.0	0.575
CO, L/min	4.5±1.4	4.5±1.4	4.4±1.4	0.663
CI, L/min/m ²	2.7±0.9	2.9±1.0	2.5±0.6	0.005*
ICU stay, days	7.9±8.6	8.1±9.4	7.7±7.6	0.788
Hospital stay, days	19.0±15.6	17.7±17.0	20.6±13.6	0.224
Ventilation, hours	75.8±162.8	88.3±190.1	58.3±113.5	0.208
Drainage loss within 48 h, mL	893.1±673.5	984.5±808.0	769.6±403.4	0.026*
Re-thoracotomy for bleeding	24 (13.6)	13 (13.4)	11 (13.5)	0.964
Permanent dialysis	6 (3.4)	2 (2.0)	4 (4.9)	0.269
Pneumonia	29 (16.4)	16 (16.6)	13 (16.0)	0.888
Sepsis	13 (7.3)	9 (9.3)	4 (4.9)	0.252
Tracheostomy	10 (5.6)	6 (6.3)	4 (4.9)	0.477
PND	2 (1.1)	0 (–)	2 (2.5)	0.210
ECMO	22 (12.4)	15 (15.6)	7 (8.6)	0.161
Intraoperative ECMO	16 (9.0)	9 (9.3)	7 (8.6)	0.067
Postoperative ECMO	6 (3.3)	6 (6.3)	0 (–)	
Central cannulation	3 (1.7)	3 (3.1)	0 (–)	0.295
Peripheral cannulation	19 (10.7)	12 (12.5)	7 (8.6)	
Veno-arterial	21 (11.8)	15 (15.6)	6 (7.4)	0.318
Veno-venous	1 (0.5)	0 (–)	1 (1.2)	
Time on ECMO, days	10.3±7.9	11.5±7.9	7.7±7.9	0.303
Successful weaning	11 (50.0)	7 (46.6)	4 (57.1)	0.367
In-hospital death	18 (10.2)	15 (15.6)	3 (3.7)	0.009*
Echocardiogram at discharge				
LVEF	65.2±6.4	66.6±7.5	64.0±5.0	0.015*
RVSF	35.2±9.5	36.5±8.5	34.1±10.2	0.174
P _{RV}	42.5±17.3	44.0±17.2	41.1±17.3	0.383

* indicates significance (P<0.05). PAP, pulmonary artery pressure; RAP, right atrial pressure; PWCP, pulmonary wedge capillary pressure; CO, cardiac output; CI, cardiac index; TPG, trans pulmonary gradient; PVR, pulmonary vascular resistances; ICU, intensive care unit; PND, permanent neurological deficit; ECMO, extracorporeal membrane oxygenation; LVEF, left ventricle ejection fraction; RVSF, right ventricle systolic function; P_{RV}, right ventricle pressure.

Table 4 Univariate risk factors analysis for in-hospital mortality and for postoperative ECMO

Risk factor analysis	Logistic regression for in-hospital mortality; univariable analysis			Logistic regression for ECMO; univariable analysis		
	P value	OR	95% CI	P value	OR	95% CI
Group 2	0.016*	0.208	0.06–0.75	0.166	0.511	0.20–1.32
Age, years	0.841	0.997	0.97–1.03	0.178	0.982	0.96–1.01
Male	0.758	0.854	0.31–2.33	0.936	0.963	0.38–2.44
BMI >30 kg/m ²	0.556	0.678	0.19–2.47	0.632	0.756	0.24–2.38
Previous PE	0.441	0.681	0.26–1.81	0.388	0.674	0.28–1.65
NYHA III-IV	0.042*	8.330	1.07–64.42	0.044*	4.653	1.04–20.80
Preoperative vasodilators	0.522	0.720	0.26–1.97	0.654	0.808	0.32–2.05
Chronic lung disease	0.017*	4.123	1.29–13.23	0.339	1.569	0.62–3.95
Restrictive lung disease	0.001*	3.114	1.57–6.20	0.261	1.480	0.75–2.93
DLCO	0.003*	0.833	0.74–0.94	0.006*	0.936	0.89–0.98
FEV ₁	0.057	0.972	0.94–1.00	0.005*	0.959	0.93–0.98
O ₂ therapy	0.008*	4.071	1.45–11.41	0.016*	3.131	1.23–7.94
Thrombophilia	0.201	0.433	0.12–1.56	0.425	0.651	0.22–1.87
Echocardiogram						
LVEF, %	0.872	1.003	0.94–1.08	0.479	0.977	0.91–1.04
RVSF, %	0.090	0.943	0.88–1.01	0.494	0.980	0.92–1.04
P _{RV} , mmHg	0.109	1.020	0.99–1.04	0.059	1.023	0.99–1.05
Tricuspidal regurgitation	0.110	1.598	0.90–2.84	0.118	1.536	0.90–2.62
Hemodynamics						
PAPs, mmHg	0.844	1.003	0.97–1.03	0.093	1.020	0.99–1.04
PAPd, mmHg	0.944	0.998	0.95–1.04	0.731	0.992	0.95–1.04
PAPm, mmHg	0.585	0.989	0.95–1.03	0.704	1.007	0.97–1.04
RAP, mmHg	0.002*	1.158	1.05–1.27	0.097	1.063	0.99–1.14
PWCP, mmHg	0.552	0.960	0.83–1.10	0.518	0.959	0.84–1.09
CO, L/min	0.010*	0.490	0.29–0.84	0.026*	0.586	0.37–0.94
CI, L/min/m ²	0.211	0.584	0.25–1.36	0.282	0.662	0.31–1.40
TPG, mmHg	0.916	0.997	0.95–1.05	0.384	1.020	0.98–1.07
RVP, UW	0.032*	1.149	1.01–1.31	0.038*	1.135	1.01–1.28
Hemodynamic classification	0.017*	2.177	1.15–4.12	0.047*	1.819	1.01–3.28
AngioCT scan involvement						
Central	0.139	2.100	0.79–5.61	0.369	1.530	0.60–3.87
Lobar	0.170	2.247	0.70–7.15	0.567	1.322	0.51–3.44
Segmental	0.957	1.043	0.22–4.92	0.737	0.798	0.21–2.98
Subsegmental	0.342	1.647	0.59–4.61	0.566	1.315	0.51–3.36

Table 4 (continued)

Table 4 (continued)

Risk factor analysis	Logistic regression for in-hospital mortality; univariable analysis			Logistic regression for ECMO; univariable analysis		
	P value	OR	95% CI	P value	OR	95% CI
Redo	0.374	2.083	0.41–10.49	0.374	2.083	0.41–10.49
X-clamp time, min	0.003*	1.010	1.00–1.01	0.062	1.008	1.00–1.02
CPB time, min	0.121	1.008	0.99–1.02	0.000*	1.012	1.01–1.02
DHCA	0.573	0.741	0.26–2.10	0.334	0.629	0.25–1.61
Periods of DHCA	0.404	0.835	0.54–1.28	0.563	0.894	0.61–1.30
Total DHCA time, min	0.503	0.991	0.96–1.02	0.813	1.003	0.98–1.03

* indicates significance ($P < 0.05$). ECMO, extracorporeal membrane oxygenation; BMI, body mass index; PE, pulmonary embolism; NYHA, New York Heart Association; DLCO, diffusion lung carbonmonoxide; FEV₁, forced expiratory volume; LVEF, left ventricle ejection fraction; RVSF, right ventricle systolic function; P_{RV}, right ventricle pressure; PAP, pulmonary artery pressure; RAP, right atrial pressure; PWCP, pulmonary wedge capillary pressure; CO, cardiac output; CI, cardiac index; TPG, trans pulmonary gradient; PVR, pulmonary vascular resistances; X-clamp time, aortic cross clamp time.




Figure 2 Kaplan-Meier overall survival analysis.

consisting of 96 patients operated in the first 9 years and group 2 with 81 patients operated in the following 8 years) the most significant figure is represented by the reduction in operative mortality. The two groups have similar demographic and preoperative characteristics, although in group 1, the patients were more decompensated, with greater impairment of lung function and thus also of the function of the right ventricle in terms of fraction of shortening and right atrial pressure.

In terms of complications after the operation, drain's loss and incidence of re-thoracotomy was higher in group one. Length of intubation was also similar. Neurological events,

particularly those transient and then reversible were slightly higher in the group 2, characterize mainly by chorea and disorientation. Also renal insufficiency requiring dialysis was also higher in this group, without significance. Further analysis would be required to analyze this finding.

Inexorably, differences in CPB management led to a significant reduction in the duration of extracorporeal circulation and aortic clamping in group 2 despite the systematic adoption of DHCA.

Need of ECMO after the operation was similar in both groups, but weaning and survival improved in the second group.

Previously, we have also analyzed the different hemodynamic profiles of our population, to identify those most at risk or not (9). As previously reported by the Canadian group, dysfunction of the right ventricle represents a risk factor for mortality (13) while the degree of PH affects the hemodynamic result after PTE: patients with PVR values greater than 1,200 dynes·sec·cm⁻⁵ are more likely to have residual PH although improved. The combination of high PH together with right ventricular dysfunction, might result in high risk of operative mortality and in these cases, associated pathologies, age, general status and expectations must be accurately weighted.

There are patients who often need targeted therapy for PH or even can take advantage of BPA after the PTE operation during the follow up. At this point the BPA can be interpreted as an additional therapeutic weapon synergistic

to surgical treatment (14,15).

There is an important factor that influences preoperative differences and then results in between groups, which in not only our selection capability. The other reason is that, since 2015 another therapeutic tool for CTEPH patient is available in our center. This is the BPA. During the second era from 2012 to 2020, for more than half of the second period, in cases where the pathology was excessively distal or the characteristics of the patient prohibitive for a PTE intervention, we had this therapeutic alternative. Many of these patients would have undergone PTE surgery in the first period given the unavailability of BPA, explaining the pre and postoperative differences of group 1 compared to group 2.

Regarding the percentage of our global population of CTEPH candidates and subjected to PTE intervention it is necessary to report as previously described, that a significant number of patients were not candidates for any type of therapy except pharmacological, due to limited anatomical involvement with low hemodynamic repercussions or patients affected by other pathologies with greater clinical and prognostic impact. Of the other CTEPH patients, the acceptability rate for PTE is approximately 80%.

Another controversial topic is the use of preoperative specific vasodilators in patients with indication to PTE. We almost routinely perform PTE on patients with this therapy, mainly oral 5-phosphodiesterase inhibitors. We did not find technical difficulties. Patients reach operation with slightly better pulmonary hemodynamics, and consequently better right ventricular functions, which have been demonstrated to impact outcomes. Furthermore, the medication before the operation serves as a drug test, eliminating in some manner the healthy vessels vasoconstriction contribution to the PH, adding degree of reversibility information.

Conclusions

The present work has many limitation due to its retrospective nature. Our population is very heterogeneous and we aware that many other and not analysed factor might influence results. However and in conclusion, our results demonstrate without any doubt that, in a dedicated center, with precise implementation protocols throughout the diagnostic and therapeutic path of a considered a rare pathology as CTEPH, they are perfectly in line with the results of centers with greater number of annual procedures. We fully agree that an expert center like ours must be able to offer the patient with CTEPH, all therapeutic

possibilities and a well-defined diagnostic path and a dedicated team regardless of the degree and severity of the pathology. Still, PTE surgery must be the first therapeutic choice in patients with CTEPH, with involvement of at least the segmental pulmonary branches, in the absence of major contraindications to the intervention.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Andrea Dell'Amore and Nizar Asadi) for the series "Mechanical Extracorporeal Cardio-Respiratory Supports in General Thoracic Surgery" published in *Current Challenges in Thoracic Surgery*. The article was sent for external peer review organized by the Guest Editors and the editorial office.

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at <http://dx.doi.org/10.21037/ccts-20-137>

Data Sharing Statement: Available at <http://dx.doi.org/10.21037/ccts-20-137>

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/ccts-20-137>). The series "Mechanical Extracorporeal Cardio-Respiratory Supports in General Thoracic Surgery" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization. The study does not require institutional ethics board approval and individual consent for this retrospective analysis was waived.

Open Access Statement: This is an Open Access article

distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. *Circulation* 2014;130:508-18.
- Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. *Chest* 1993;103:685-92.
- Simonneau G, Torbicki A, Dorfmüller P, et al. The pathophysiology of chronic thromboembolic pulmonary hypertension. *Eur Respir Rev* 2017;26:160112.
- Jenkins D, Madani M, Fadel E, et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. *Eur Respir Rev* 2017;26:160111.
- Savini C, Murana G, Di Eusanio M, et al. Safety of single-dose histidine-tryptophan-ketoglutarate cardioplegia during minimally invasive mitral valve surgery. *Innovations (Phila)* 2014;9:416-20.
- Mikus PM, Mikus E, Martín-Suárez S, et al. Pulmonary endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results. *Eur J Cardiothorac Surg* 2008;34:159-63.
- Mikus PM, Dell'Amore A, Pastore S, et al. Pulmonary endarterectomy: is there an alternative to profound hypothermia with cardiocirculatory arrest? *Eur J Cardiothorac Surg* 2006;30:563-5.
- Vuylsteke A, Sharples L, Charman G, et al. Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. *Lancet* 2011;378:1379-87.
- Martin-Suarez S, Gliozzi G, Fiorentino M, et al. Role and management of extracorporeal life support after surgery of chronic thromboembolic pulmonary hypertension. *Ann Cardiothorac Surg* 2019;8:84-92.
- Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. *Ann Thorac Surg* 2003;76:1457-62; discussion 1462-4.
- Pacini D, Leone A, Di Marco L, et al. Antegrade selective cerebral perfusion in thoracic aorta surgery: safety of moderate hypothermia. *Eur J Cardiothorac Surg* 2007;31:618-22.
- Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. *J Thorac Cardiovasc Surg* 2011;141:702-10.
- de Perrot M, Thenganatt J, McRae K, et al. Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension. *J Heart Lung Transplant* 2015;34:369-75.
- Wiedenroth CB, Liebetrau C, Breithecker A, et al. Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. *J Heart Lung Transplant* 2016;35:591-6.
- Shimura N, Kataoka M, Inami T, et al. Additional percutaneous transluminal pulmonary angioplasty for residual or recurrent pulmonary hypertension after pulmonary endarterectomy. *Int J Cardiol* 2015;183:138-42.

doi: 10.21037/ccts-20-137

Cite this article as: Martin-Suarez S, Gliozzi G, Loforte A, Niro F, Fiorentino M, Cavalli GG, Palazzini M, Saia F, Barbera N, La Monaca M, Galiè N, Pacini D. Pulmonary thrombo-endarterectomy for chronic thromboembolic pulmonary artery hypertension. *Curr Chall Thorac Surg* 2021;3:13.